What is the recommended dosage of Deviry (Duphaston) tablet for Chronic Obstructive Pulmonary Disease (COPD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 5, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

From the Guidelines

I strongly advise against using Deviry (Duphaston) tablets for the treatment of Chronic Obstructive Pulmonary Disease (COPD), as they are not a standard or recommended medication for this condition. The medication Deviry, also known as Duphaston, is actually a progestin used in the treatment of various gynecological conditions, not COPD. According to the 2023 Canadian Thoracic Society guideline on pharmacotherapy in patients with stable COPD 1, the recommended treatments for COPD include inhaled maintenance therapy with long-acting bronchodilators (LABDs), long-acting muscarinic antagonists (LAMAs), and inhaled corticosteroids (ICS), among others.

Key points to consider in COPD treatment include:

  • The alleviation of symptoms, particularly dyspnea, and improvement of health status as primary treatment goals
  • The use of LABD maintenance therapy in all individuals with persistent symptoms, even mild, with COPD
  • The recommendation for LAMA/LABA dual therapy in individuals with moderate to severe dyspnea and reduced health status
  • The importance of preventing acute exacerbations of COPD (AECOPD) and the choice of therapy based on the risk of future AECOPD

It is essential to consult a healthcare provider for proper diagnosis and treatment of COPD, as medication regimens are individualized based on disease severity, symptoms, exacerbation history, and other health conditions. Never adjust medication without medical supervision, as proper treatment is crucial for managing COPD symptoms and preventing exacerbations.

From the Research

Recommended Dosage of Deviry (Duphaston) Tablet for COPD

There are no research papers to assist in answering this question, as none of the provided studies mention the use of Deviry (Duphaston) tablets for the treatment of Chronic Obstructive Pulmonary Disease (COPD) 2, 3, 4, 5, 6.

Alternative Treatments for COPD

  • The management of COPD is fundamentally still heavily dependent on the use of bronchodilators and corticosteroids 4.
  • Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists may be used for the treatment of stable COPD 5.
  • Medroxyprogesterone may be associated with significant improvements in blood pH, PCO2, dyspnea, and daily duration of noninvasive ventilation using in patients with COPD exacerbation 6.

Key Findings

  • Triple therapy (inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists) may reduce rates of moderate-to-severe COPD exacerbations and improve health-related quality of life 5.
  • Medroxyprogesterone may improve blood gases and short-term hospital outcomes in patients with COPD treating with noninvasive ventilation 6.

Related Questions

What is the optimal medication regimen for a patient with severe chronic obstructive pulmonary disease (COPD)?
What is the cheapest generic inhaled long‑acting beta‑agonist (LABA) combined with an inhaled corticosteroid (ICS)?
Is it accurate that COPD is diagnosed when post‑bronchodilator FEV1/FVC is <0.7, that symptomatic COPD should be treated with a long‑acting β2‑agonist (LABA) plus a long‑acting muscarinic antagonist (LAMA), and that inhaled corticosteroids are used only for exacerbations or asthmatic features?
How should a low‑dose long‑acting β2‑agonist (LABA) be prescribed for an adult with mild ventilatory disorder, ensuring no contraindications?
In a 68-year-old man with severe chronic obstructive pulmonary disease (COPD) who has had three exacerbations in the past year (including one hospitalization), is currently on triple inhaler therapy (fluticasone‑umeclidinium‑vilanterol) plus albuterol as needed, has an absolute eosinophil count of 150 cells/µL, and a prolonged QT interval (QTc 510 ms), which long‑term therapy should be recommended to reduce the risk of future exacerbations: dupilumab, azithromycin, roflumilast, or prednisone?
What is the significance of unstable lie in patients with polyhydramnios (excess amniotic fluid)?
What is the management of a retained second twin (fetus) in a multiple gestation pregnancy?
What is the gastrointestinal (GI) point of view (POV) for a drop in hemoglobin (Hb)?
What is the starting dose for isoproterenol (isoprenaline) infusion?
Does minoxidil cause hypertriglyceridemia?
What are the bleeding parameters based on spinal anesthesia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.